ACC 2024 | IVUS-DCB

Drug-coated balloons (DCB) have proven to be effective in the treatment of femoropopliteal pathology, although they entail complications such as recoil, residual stenosis, and dissection.

ACC 2024

Their outcomes could be improved through proper and enhanced vessel preparation, both before and after the procedure. Intravascular ultrasound (IVUS) offers the advantage of characterizing plaque and assessing vessel diameter.

The aim of this study was to compare IVUS-guided angioplasty vs. conventional angiography in DCB (IN.PACT, Medtronic) treatment of femoropopliteal disease. Researchers included a total of 237 patients from 7 centers in Korea; these subjects were randomized to IVUS (n=119) and angiography (n=118). The primary endpoint was primary patency (PP) at 12 months.

The average age was 69 years; 85.7% of patients were men, 74.8% had claudication, and the rest had critical limb ischemia. Regarding characteristics, most lesions were TASC II C/D (67.2%).

Read also: ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus.

Technical success was achieved in 76.5% of IVUS patients and 61% of those undergoing angiography. Post-procedure ankle-brachial index (ABI) was 0.99 and 0.93, respectively. When evaluating PP, better outcomes were observed in the IVUS arm (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.25-0.85; Log-rank P= 0.01). Additionally, considering secondary events, IVUS-guided treatment showed better results in terms of revascularization-free vessel (HR, 0.41; 95% CI, 0.19-0.90; Log-rank P= 0.03) and sustained clinical improvement (HR, 0.45; 95% CI, 0.23-0.86; Log-rank P=0.02).

In conclusion, IVUS guidance significantly improved DCB treatment outcomes in femoropopliteal disease, with better primary patency, greater freedom from new revascularization, and clinical improvement at 12 months.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Comparación de angioplastia dirigida por IVUS vs dirigido por angiografía en el tratamiento con balón con drogas para territorio femoropoplíteo. 

Reference: Presentado por Dr. Young-Guk Ko en ACC.24 Late-Breaking Clinical Trials, 6-8 de abril, Atlanta.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...